MARKET

LTGO

LTGO

Latigo Biotherapeutics, Inc.
NASDAQ
23.21
+0.73
+3.25%
Opening 09:49 09/04 EDT
OPEN
22.68
PREV CLOSE
22.48
HIGH
23.55
LOW
22.68
VOLUME
14.63K
TURNOVER
--
52 WEEK HIGH
25.93
52 WEEK LOW
17.22
MARKET CAP
1.54B
P/E (TTM)
-1.1536
1D
5D
1M
3M
1Y
5Y
1D
Latigo Biotherapeutics Q2 EPS $(27.59) Up From $(36.52) YoY, Sales $0.00, Same YoY
Benzinga · 16h ago
*Latigo: Cash and Cash Equivalents Projected to Fund Operating Plans Into 2029 >LTGO
Dow Jones · 17h ago
*Latigo Biotherapeutics 2Q Loss $25.8M >LTGO
Dow Jones · 17h ago
*Latigo Biotherapeutics 2Q Loss/Shr $27.59 >LTGO
Dow Jones · 17h ago
Latigo Biotherapeutics, Inc. reports Q2 results
Seeking Alpha · 17h ago
Press Release: Latigo Biotherapeutics Reports -2-
Dow Jones · 17h ago
Press Release: Latigo Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Dow Jones · 17h ago
Analysts Offer Insights on NA Companies: Latigo Biotherapeutics, Inc. (LTGO), Golar LNG (GLNG) and Mobility Global Inc (MBGL)
TipRanks · 2d ago
More
About LTGO
Latigo Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Pain represents one of the largest and most pervasive therapeutic markets in the United States, driving an estimated 250 million prescriptions annually across acute and chronic settings.

Webull offers Latigo Biotherapeutics, Inc. stock information, including NASDAQ: LTGO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LTGO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading LTGO stock methods without spending real money on the virtual paper trading platform.